Future-Ready MF Care: Better Outcomes Through Research

In the final segment of a roundtable discussion moderated by Prithviraj Bose, MD, leading myelofibrosis experts share their forward-looking insights on treatment advancements, focusing on JAK inhibitors and anemia-targeted therapies. The panel reflects on the expanding therapeutic landscape, highlighting the availability of four distinct JAK inhibitors—each offering unique advantages in clinical management.

The discussion emphasizes that while spleen response has historically dominated endpoints, anemia—long associated with poor prognosis and reduced quality of life—is gaining recognition as a key treatment focus. Agents like momelotinib and other emerging anemia therapies are seen as game changers, especially when used early to prevent transfusion dependence.